Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial

PURPOSE: The ACOSOG (American College of Surgeons Oncology Group) Z9001 (Alliance) study, a randomized, placebo-controlled trial, demonstrated that 1 year of adjuvant imatinib prolonged recurrence-free survival (RFS) after resection of primary GI stromal tumor (GIST). We sought to determine the path...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Corless, Christopher L., Ballman, Karla V., Antonescu, Cristina R., Kolesnikova, Violetta, Maki, Robert G., Pisters, Peter W.T., Blackstein, Martin E., Blanke, Charles D., Demetri, George D., Heinrich, Michael C., von Mehren, Margaret, Patel, Shreyaskumar, McCarter, Martin D., Owzar, Kouros, DeMatteo, Ronald P.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2014
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4026579/
https://ncbi.nlm.nih.gov/pubmed/24638003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.2046
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller